Vascular a ccess access for Dialysis a surgeon s perspecti e v. some observations

Similar documents
CHAPTER 5. Haemodialysis. Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald

Introduction to the Native Arteriovenous Fistula: A primer for medical students and radiology residents

AMMAR SERAWAN, MD. Ain Wzain Hospital. April 21, 2012 Vascular Access Study Workshop

Vascular Access for Haemodialysis. Mike Stephens

Sichol sooksee,rn. Hemodialysis Unit Rajavej Chiang Mai Hospital

Technical and Clinical Barriers to Implementing an Optimal Case Mix of Vascular Access

ASDIN 7th Annual Scientific Meeting

Medical Director/Surgeon as Partners WebEx February 11, 2010

CATHETER REDUCTION. Angelo N. Makris, M.D. Medical Director Chicago Access Care

Evaluation of AVF and AVG

UPDATE IN VASCULAR ACCESS Mercedeh Kiaii MD FRCPC Rick Luscombe RN BSN CNeph(C) Elizabeth Lee MD FRCPC

PREVENTION AND TREATMENT OF ANEURYSMS OF AUTOGENOUS DIALYSIS ACCESSES STEPHEN L. HILL, M.D.,F.A.C.S

ASDIN 8th Annual Scientific Meeting

Why Can't I Cannulate This Fistula? Fistula Immaturity: The Simple But Critical Steps for a Functioning (Mature) AVF

Sid Bhende MD Sentara Vascular Specialists April 28 th Dialysis Access Review: Understanding the Access Options our Patients Face

What s on the Horizon in Dialysis Access? Libby Watch, MD, FACS Miami Cardiac & Vascular Institute

Vascular access. The KidneyCare Audit

Vascular Access Options for Apheresis Medicine

Distal Hypoperfusion Ischemic Syndrome (DHIS)

CHAPTER 4 METHOD AND LOCATION OF DIALYSIS. Nancy Briggs Kylie Hurst Stephen McDonald Annual Report 35th Edition

HD Scanning: Velocities and Volume Flow

Vascular Access Care Plans: How Can a Care Plan Really Improve Care and Make Everyone s Job Easier?

Selection of Permanent Hemodialysis Vascular Access

Dr. Murty Mantha MD FRACP Cairns Base Hospital Cairns. DNT 2011 Hunter Valley

Vascular Access for Patients affected by non Renal Disorders. Eric S Chemla St George s vascular Institute London UK

Vascular Access Study Overview and Implementation

UC SF. End Stage Renal Disease. National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) BUT-- No Cephalic Vein What s Next

St George Hospital Renal Department Internal Only

Cannulation Techniques Webinar

It is important to learn all you can about your access so you can take better care of yourself.

Victoria Chapman BS, RN, HP (ASCP)

Case #1. Case #1- Possible codes. Unraveling the -59 modifier. Principles of Interventional. CASE 1: Simple angioplasty

Nursing Care of the Dialysis Patient. Adrian Hordon, MSN, RN

Fistula/Graft Protection. Leslie Dork Renal Medicine Associates

CHAPTER 12 END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND. Stephen McDonald. Matthew Jose. Kylie Hurst INDIGENOUS 12-1

Pitfalls in pushing fistulas ----

7/7/2015. Objectives. Pros and Cons of Buttonhole Cannulation

Does cannulation technique impact arteriovenous fistula and graft survival? Maria Teresa Parisotto CANNT 2017 Halifax October 20 th, 2017

Acceptance onto dialysis guidelines: St George Hospital

2006 NKF-DOQI Guidelines Preferred Vascular Access Order 1. Radiocephalic (wrist) fistula 2. Brachiocephalic (elbow) fistula 3. Basilic vein transposi

Interventions for AV-Shunt stenosis: What works best PTA, Stent or DCB?

Novel solutions for access challenges

AV ACESS COMPLICATIONS. Ass. Prof. Dr. Habas

End Stage Kidney Disease Among Indigenous Peoples of Australia and New Zealand

BUTTONHOLE CANNULATION

IN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators

Chapter 12. End Stage Kidney Disease in Indigenous Peoples of Australia and Aotearoa/New Zealand. ANZDATA Registry 39th Annual Report

Preservation of Veins and Timing for Vascular Access

Tale of Neglected Aneurysm

Juxta-anastomotic stenoses: angioplasty or surgery (or when/why should we wait)?

Postoperative AV Fistula Evaluation. Postoperative examination protocol. Postoperative AVF Protocol. Hemodialysis Access Surveillance

End Stage Renal Disease (ESRD) Network Learning and Action Network (LAN) Series: Bloodstream Infection (BSI) Quality Improvement Activity

The HeRO Graft. Shawn M. Gage, PA Division of Vascular Surgery Duke University Medical Center

St George Hospital Renal Department Internal Policy

AV Access Technology and Innovation DEVICES CHANGING HOW WE THINK ABOUT VASCULAR ACCESS

Renal Physicians Association Kidney Quality Improvement Registry, Powered by Premier, Inc non-mips Measure Specifications

Surgical Options in Thrombectomy for Non-Surgeons

Renal Patient s Information Leaflet

MIHÁLY TAPOLYAI, MD, FASN, FACP Associate Professor, Louisiana State University; Shreveport, Louisiana, USA Associate Professor; University of Hawai

Steal Syndrome: The Role of the Vascular Lab

Medical Emergencies in Dialysis Patients

STOCK and FLOW. ANZDATA Registry 2011 Report CHAPTER 1 STOCK & FLOW. Blair Grace Kylie Hurst Stephen McDonald 1-1

COVERA Vascular Covered Stents in the Management of Dysfunctional AV Access

PROVINCIAL STANDARDS & GUIDELINES

JVA ISSN Hemodialysis vascular access management in the Netherlands. Introduction ORIGINAL ARTICLE


COVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study

Dialysis Overview S J Fratesi MD FRCS

Kidney Decisions Aid

Recurrent lesions in AV access & Initial DCB experience in India

Superficialización de la vena basílica. Pierre BOURQUELOT, Paris

Proven Performance Through Innovative Design *

Lutonix in AV fistula and Early look AV IDE trial data

Quality ID #329: Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis National Quality Strategy Domain: Effective Clinical Care

Hemodialysis Fistula Maturation Consortium

CHAPTER 12 END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND. Matthew Jose Stephen McDonald Leonie Excell

The Role of LUTONIX 035 DCB in AV Fistula Dysfunction Management in our Practice

NKF K/DOQI GUIDELINES

UW MEDICINE PATIENT EDUCATION. Hemodialysis. A treatment option for kidney disease. Treatment Options for Kidney Disease

Assessment, Monitoring, and. Svetlana (Lana) Kacherova, ESRD Network 18, QI Director WebEx session, December 18, 2008

Treatment choices for someone with Stage 5 kidney disease are:

What vascular access for which patient : obesity

Haemodialysis central venous catheter-related sepsis management guideline Version 3. NAME M. Letheren Chair Clinical Effectiveness Advisory Group

VA Session: A Team-Based Approach to Solving Vascular Access Problems. October 7, 2016

KDOQI Guidelines. Overview. Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium

Measure #330: Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days National Quality Strategy Domain: Patient Safety

First experience with DCB for treatment of dialysis access stenosis The Greek experience

The Buttonhole Technique for AV Fistula Cannulation

CHAPTER 3 ARTERIOVENOUS ACCESS: INFECTION, NEUROPATHY AND OTHER COMPLICATIONS

Difference in practical dialysis therapy between East Asia and US/EU

Access Preservation: Recurrent Central Venous Stenosis, Pacemaker Wires and other Nightmares. Who am I? Disclosures

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality

Ultrasound and the dialysis patient

CSI (Clinical Scenario Investigation): Hyperkalemia

National Surveillance System for Dialysis Centre and Dialysis Associated Diseases

MANITOBA RENAL PROGRAM

Dialysis and Transplantation Audit

CHAPTER 2. Prevalence of Renal Replacement Therapy for End Stage Kidney Disease

Transcription:

Vascular access for Dialysis a surgeon s perspective e. some observations

Age of New Haemodialysis Patients 2005 Australia Number (Total=1957) 0.7% 3% 5% 10% 15% 20% 26% 19% 2% 0-14 15-24 25-34 35-44 45-54 55-64 65-74 75-84 >=85 No. Pats. 14 38 104 170 303 414 514 863 37

Method and Location of Dialysis 2000-2005 Number of Patients t 5000 SAT HD 3629 (43%) HOSP HD 2289 (27%) 5000 4500 CAPD 1027 (12%) 4500 4000 HOME HD 799 (9%) 4000 3500 APD 784 (9%) 3500 3000 2500 2000 1500 1000 500 0 2000 2001 2002 2003 2004 2005 3000 2500 2000 1500 1000 500 0

RPAH Waiting time for Kidney Transplant in 2006 (n=69) 25 22 20 Deceased Donor Living Donor 15 10 5 1 2 3 2 2 0 Pre- Emptive 1m-1yr 1-2yr 2-3yr 3-4yr 4-5yr >5yr

Stock and Flow of Haemodialysis Patients 2001-2005 Number of Patients 9000 8000 7000 6000 5000 4000 3000 2000 1000 0 New Patients Transplants Perm. Transfer Deaths No. Dialysing 6717 Patients t 2001 2002 2003 2004 2005

Pr robability of surviv val 0.00 0.25 0.50 0 0.75 1.00 0 Patient Survival - HD at 90 days Censored for Transplant Australia 1993-1995 (1907) 1996-1998 (2462) 1999-2001 (3156) 2002-20042004 (3506) 0 1 2 3 4 5 Years

CRF in Australia 1. Number of kidney failure patients in Australia could triple 2. Dialysis patient number increasing by 7% per year 3. 47% of new patients are over 65 years old 4. Commonest treatment option is satellite haemodialysis 5. Transplantation is not a viable option for most patients 6. Haemodialysis is the commonest long term treatment 7. Death is commonest endpoint 50% at 5 years

Long term reliable vascular access 1. Demonstrate why AVF are better than AVG 2. Ask who are the decision makers for choice of vascular access? 3. The role of central venous catheters? 4. A plan for maximising AVF 5. Surveillance of AVF 6. Home versus satellite haemodialysis

K Polkinghorne/ANZDATA 2003

Association of Angioaccess and Mortality Haz zard Rat tio 3 2.5 2 1.5 1 0.5 0 Ref 1.24 0.097 2.54 17 1.7 <0.001 0.148 (2528) (402) (129) (28) AV Native AV Synthetic Tunnelled CV Catheter Type of Angioaccess Non-Tunnelled CV Catheter K Polkinghorne/ANZDATA 2003

Access Intervention in Previous Twelve Months - December 2005 n = Number of Patients Revision of Access Declotting of Access AVF AVG CVC AVF AVG CVC Australia n=6717 12% 35% 18% 5% 26% 14% Diabetics n=1660 12% 41% 17% 6% 29% 13% F emale n=2672 13% 35% 18% 6% 25% 15% AVG in 2005 were: 1. five times more likely to clot 2. three times more likely to require revision 3. less satisfactory than central venous catheters

Type of Access for Haemodialysis Australia December 2005 CVC AVG AVF 76% 74% 77% Only significant factors correlating with use of AVG are length of time 67% 82% on dialysis and the HD centre 12% 10% 13% 18% 9% All Pts Diabetic Non Diab Female Male (n=6717) (n=1660) (n=5057) (n=2672) (n=4045)

2003 Western Australia AVG 12% Catheters 18% 9% 3% Northern Territory AVG 6% Catheters 6% 8% Queensland AVG 16% Catheters 10% South Australia AVG 6% Catheters 4% New South NSW 20% Wales/ACT 10% AVG 30% Catheters 7% ACT 36% Victoria AVG 9% Catheters 8% 8% 8% Tasmania AVG 1% Catheters 20%

Mode of HAEMODIALYSIS NSW December 2004 100 80 60 40 20 0 NSW TEMP CVC Synthetic Native L'POO OOL WEST NSW STG TGH WGN GNG NEW EWC RPA/CO CON RNSH percent

First Haemodialysis Access Initial RRT By Referral - Australia Perce entage 60 80 100 40 16 19 19 29 4 31 33 4 3 34 55 43 42 46 49 Non-Tunnel CVC Tunnel CVC AVG AVF 0 20 52 46 46 Mar 04 Dec 05 Dec 04 Early 1 10 2 10 Late 1 8 Dec 04 Mar 04 Dec 05

Mode of INITIAL vascular access NSW in 2004 100 80 perce ent 60 TEMP 40 CVC Synthetic 20 Native 0 WEST L'POOL WGNG NSW NSW NEWC RNSH RPA/CON

h th d isi k s f h i who are the decision makers for choice of vascular access in your hospital?

Decision i makers 1. Nephrologist 2. Patient t 3. Patient s family 4. Dialysis nursing staff 5. Vascular surgeon time ease of surgery $$$

Central Venous Catheters temporary late presentation, BMI>35 and female necessary for bridging to native or synthetic AVF high complication rate thrombosis insertion? where and when? long term solution

Central Venous Catheters

Imaging of the IJV

Non-tunneled CVCs avoid use in neck

Positioning CVC junction of SVC and right atrium in sitting position risk of thrombosis right atrium

SVC obstruction - mechanical injury to SVC

Biofilm inevitable it and on outer side of catheter t - not tin the lumen. Bacteria adhere with source being at time of insertion or circulating organisms at any time thereafter. Usually S. aureus or S. epidermidis and therefore skin source. Patient to patient spread of staphylococcus demonstrated by?? Lab technique identification and therefore implication dialysis nursing staff and not patient source. Multiple options for catheter locking solutions. Need for perhaps p determined by Catheter Related Bacteraemia rate (events/1,000 catheter days). If CRB rate low, randomised trials have difficulty showing advantages over heparin alone. Centres should monitor CRB rates should be about 2/1,000 days. RCTs show Gentamicin to best at lowering CRB rate but antibiotic resistance rate unacceptable. Next best is. with 4% citrate. Not available in Australia ampoule worth about 12 Euro.

Long term reliable vascular access 1. Demonstrate why AVF are better than AVG 2. Ask who are the decision makers for choice of vascular access? 3. The role of central venous catheters? 4. A plan for maximising AVF 5. Surveillance of AVF 6. Home versus satellite haemodialysis

FISTULA FIRST National Vascular Access Improvement Initiative initiative to increase AVF prevalence started Northwest network in 2003 aim for 50% AVF

The team approach 1. Designate staff member in dialysis facility (RN if feasible) responsible for vascular access 2. Assemble multi-disciplinary vascular access team 3. Representatives of all key disciplines including access surgeons, ultrasonographers and interventionalists. 4. Investigate and track all non-avf access placements, and AVF failures 5. Benchmark against others

Referral 1. Nephrologist/skilled nurse performs appropriate evaluation and physical exam prior to surgery referral. 2. Nephrologist refers for vessel mapping where feasible, prior to surgery referral. 3. Nephrologist refers patients to surgeons for AVF only evaluation. Surgery scheduled with sufficient lead-time for AVF maturation. 4. Nephrologist defines AVF expectations to surgeon

Vascular access surgeon Nephrologists refer to surgeons willing and able to meet the standards and expectations. Surgeons utilize current techniques for AVF placement including vein transposition. Surgeons ensure mapping is performed for any patient t not clearly suitable for AVF based only on physical exam. Surgeons are evaluated on frequency, quality and patency of access placements. Surgeons work with nephrologists to plan for and place secondary AVFs in suitable AV graft patients.

AV grafts to AVF evaluate and identify every AV graft patient for possible secondary AV fistula conversion, and document the plan in the patient s t record. examine outflow vein of all graft patients with sleeves up during dialysis treatments (minimum frequency, monthly). refer to surgeon for placement of secondary AVF before failure of AVG.

Cannulation Facility uses best cannulators and best teaching tools. Dialysis staff use specific protocols for initial dialysis treatments Assign the most skilled staff to patients with new AVFs Facility offers option of self-cannulation to patients who are interested and able.

Surveillance Facilities adopt standard procedures for monitoring, surveillance, and timely referral for the failing AVF. Nephrologists, interventional radiologists, and surgeons adopt standard criteria, and a plan for each patient Review data monthly or quarterly in facility staff meetings. Present and evaluate data trended over time

? experience of surgeon

Obese patients

AVF vs AVG Saphenous vein loops unpopular because of aneurysms and stenoses. Large numbers of brachiocephalic and brachiobasilic AVF (latter performed as two stage procedure). For example, 70% of native vein AVF were in upper arm in large and recent series from University it of Miami. i Same trend in Europe. Upper arm fistulae associated with high flows and cephalic arch stenoses interesting relationship between these two problems, particularly with respect to dilation and effect cardiac output. High venous return pressures can be a result of high flow. See later discussion on flow monitoring.

Brachiocephalic fistula

Surveillance of fistulae 1. Improve patient care reliability and predictability of access prolong and preserve access vessels 2. Reduce access related costs morbidity related home haemodialysis

sleeves up and arm up

Movie 1340

Movie 1347

Movie 1344

Venous hypertension

Whilst on dialysis Ease of cannulation Ability to rotate cannulation points Arterial inflow pressures Pump speed Venous return pressures Decannulation bleeding times

Distribution of Blood Flow Rates 4500 4000 Number of Patients 5000 Mar 2004 (5924) 3500 3000 2500 2000 1500 1000 500 0 Dec 2004 (6206) Dec 2005 (6717) Australia 200-249 250-299 300-349 350-399 >=400 mls/min

Ultrasound

dysfunction hypothesis Fistula stenosis causes graft dysfunction and dysfunction precedes and accurately predicts thrombosis Surveillance relies on:- 1. Reproducible measurements 2. Stenosis progressing slowly 3. Other factors such as hypercoagulability, low BP etc do not influence 4. Correlation with clinical examination

a must get!

Digital Ischaemia incidence 1 3% invariably diabetic patient radial = brachial incidence treat by banding or ligation DRIL procedure

Surveillance recommendations 1. High quality and continuous clinical assessment 2. Initial ultrasound assessment dialysis nurse driven 3. Early intervention

Mr T

5. Cannulation techniques Description three cannulation techniques: rope ladder or snail track for AVGs and good veins provided aneurysms do not develop in latter area technique which is prone to aneurysm formation, particularly in high flow fistulae button hole which I now have a very revised and more positive appreciation of. Should not be confused with area cannulation technique. button hole is a very precise technique and very operator dependent. Preparation and angle of entry very important, initially with sharp needles. Nursing recommendation that it be employed by limited number of staff for a given patient. No nurse should cannulate ate a given fistula without having witnessed another with knowledge of that given fistula.

educated smiling home HD patient